Abstracts Archive - Page 2148 of 2425 - ACR Meeting Abstracts

Abstract Number: 1556 • 2013 ACR/ARHP Annual Meeting
Paradoxical Psoriasis: Experience Of a Biological Therapy Monographic Unit
Maria Luz Garcia Vivar¹, Silvia Perez Barrio², EVA Galindez Agirregoikoa³, Catalina Gomez Arango⁴, Jose Francisco Garcia Llorente⁵, Rosa Izu Belloso⁶, Esther Ruiz Lucea⁵, Ignacio Torre Salaberri⁷ and Jesus Maria Careaga Alzaga⁸, ¹RHEUMATOLOGY, Rheumatology department, Basurto University Hospital., BILBAO, Spain, ²DERMATOLOGY, Dermatology Department.Basurto University Hospital., BILBAO, Spain, ³RHEUMATOLOGY, Rheumatology Department. Basurto University Hospital., BILBAO, Spain, ⁴Rheumatology, Hospital Universitario Basurto, Bilbao, Spain, ⁵RHEUMATOLOGY, Rheumatology department. Basurto University Hospital., BILBAO, Spain, ⁶DERMATOLOGY, Dermatology Department. Basurto University Hospital. Bilbao, BILBAO, Spain, ⁷Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ⁸DERMATOLOGY, Dermatology department. Basurto University Hospital., BILBAO, Spain
Background/Purpose: Anti TNF therapy’s efficacy in controlling cutaneous psoriasis has widely been proven, but development of paradoxical psoriasis (PPs) as a side effect can occur.…
Abstract Number: 1557 • 2013 ACR/ARHP Annual Meeting
Assessing The Real Life Impact Of Psoriatic Arthritis On Disability, Quality Of Life, and Provider Satisfaction
M. Elaine Husni¹, Daniel Duch² and Neil J. Korman³, ¹Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ²Curatio CME Institute, Exton, PA, ³Case Western Reserve Univ (Uni, University Hospitals Dermatolo, Cleveland, OH
Background/Purpose: Despite the availability of more targeted therapies for psoriatic arthritis (PsA), an assessment of the impact these have had on patient well-being has not recently…
Abstract Number: 1558 • 2013 ACR/ARHP Annual Meeting
Drug Trends In Psoriatic Arthritis
Arane Thavaneswaran¹, Gideon Kalman-Lamb¹, Teneille Loo², Vinod Chandran³ and Dafna D. Gladman³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Medicine, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is now recognized as a potentially severe form of arthritis which requires aggressive medical therapy. The aim of this study was…
Abstract Number: 1559 • 2013 ACR/ARHP Annual Meeting
Cyclophosphamide and Rituximab Combination Treatment For Severe Systemic Lupus erythematosus is Effective and Well Tolerated
Ali Shahzad¹, Farheen Jafri², Bisharah Rizvi², Xiongce Zhao³, Meryl Waldman³ and Sarfaraz A. Hasni⁴, ¹National Institute of Arthritis, Musculoskeletal and skin diseases, NIAMS/NIH, Bethesda, MD, ²R-Research, Hamilton, NJ, ³NIDDK/NIH, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is often complicated by resistance or partial response to initial immunosuppressive regimen and flares after initial response. Optimal management of…
Abstract Number: 1560 • 2013 ACR/ARHP Annual Meeting
Clinical Characterization Of Anti-CCP+Ve Systemic Lupus Erythematosus Patients
Samera Vaseer^1,2 and Eliza Chakravarty³, ¹Rheumatology, University Of Oklahoma, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is a heterogeneous autoimmune disease characterized by the presence of autoantibodies and manifestations of numerous organ systems. One of the most common SLE…
Abstract Number: 1521 • 2013 ACR/ARHP Annual Meeting
Latent Tuberculosis Screening and Treatment In Ankylosing Spondylitis Patients Eligible For Anti-TNF Therapy In Endemic Area
Renata Miossi¹, Karina Rossi Bonfiglioli¹, Carla G.S. Saad², Ana Cristina Ribeiro¹, Julio C. B. Moraes² and Eloisa Bonfá¹, ¹Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Reumatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Anti-TNF agents have emerged as an important treatment for rheumatic diseases, particularly for ankylosing spondylitis (AS). Screening and treatment of latent tuberculosis infection (LTBI)…
Abstract Number: 1522 • 2013 ACR/ARHP Annual Meeting
Remission In Spondyloarthritis : ASDAS and Basdai Thresholds From a Prospective Real Life Study
Marie Godfrin-Valnet¹, Marc Puyraveau² and Daniel Wendling¹, ¹Service de Rhumatologie, Minjoz University Hospital, Besancon, France, ²Clinical Methodology Center, CHU, Besançon, France
Background/Purpose: Remission is the current target of management of chronic rheumatic diseases. Whereas in rheumatoid arthritis remission criteria have been recently proposed, in spondyloarthritis, no…
Abstract Number: 1523 • 2013 ACR/ARHP Annual Meeting
Presence Of Peripheral Arthritis Delays Spinal Radiographic Progression In Ankylosing Spondylitis: Observation Study Of Korean Spondyloarthropathy Registry (OSKAR) Over 5 Years
Tae-Jong Kim¹, Seunghun Lee², Kyung-Bin Joo³, Dong-Jin Park⁴, Yong-Wook Park⁴, Shin-Seok Lee⁵ and Tae-Hwan Kim⁶, ¹Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ²Department of Radiology, Department of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Department of Radiology, Department of Radiology, Hanynag University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁴Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ⁵Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ⁶Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: The most unique feature in ankylosing spondylitis (AS) is subchondral eburnation and syndesmophytes, possibly leading to ankylosis and spinal fusion. So far a clear…
Abstract Number: 1525 • 2013 ACR/ARHP Annual Meeting
Measurement Of Lateral Spinal Flexion and Schober Is Sufficient To Be Informed About Spinal Mobility In Patients With Ankylosing Spondylitis: 12-Year OASIS Results
Sofia Ramiro¹, Robert Landewé², Désirée van der Heijde³, Carmen Stolwijk⁴, Maxime Dougados⁵, Filip Van den Bosch⁶ and A.M. van Tubergen⁷, ¹Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁵Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: We have shown that spinal mobility gets impaired in a fixed order in ankylosing spondylitis (AS), with the highest impairment in lumbar spine. We…
Abstract Number: 1526 • 2013 ACR/ARHP Annual Meeting
Stable Clinical and MRI Response In Patients With Early Axial Spondyloarthritis After 3 Years Of Continuous Treatment With Etanercept, Data Of The Esther Trial
In-Ho Song¹, Kay-Geert A. Hermann², Hildrun Haibel¹, Christian Althoff³, Denis Poddubnyy⁴, Joachim Listing⁵, Anja Weiss⁶, Ekkehard Lange⁷, Bruce Freundlich⁸, Martin Rudwaleit⁹ and Joachim Sieper⁴, ¹Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ²Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵German Rheumatism Research Center, Berlin, Germany, ⁶German Rheumatism Research Centre, Berlin, Germany, ⁷BU Specialty Care, Pfizer Pharma AG, Berlin, Germany, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Endokrinologikum, Berlin, Germany
Background/Purpose: < style="text-align: justify;">In patients with early axial spondyloarthritis (SpA) with a disease duration of 10 years) where BASDAI50 response rates of 47%…
Abstract Number: 1527 • 2013 ACR/ARHP Annual Meeting
Routine Assessment Of Patient Index Data 3 Scores Correlate Well With Bath Ankylosing Spondylitis Disease Activity Index In The Assessment Of Disease Activity and Monitoring Progression Of Ankylosing Spondylitis
Abhijeet Danve¹, Kiana Vakil-Gilani², Anusha Reddy², Annan Sheffield³, Alexis Dinno⁴ and Atul A. Deodhar⁵, ¹Rheumatology, Oregon Health and Science University, Portland, OR, ²Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ³Portland State University, Portland, OR, ⁴School of Community Health, Portland State University, Portland, OR, ⁵Oregon Health and Science University, Portland, OR
Background/Purpose: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a composite tool unique to measure disease activity in ankylosing spondylitis (AS) just as Disease Activity…
Abstract Number: 1528 • 2013 ACR/ARHP Annual Meeting
Patient-Tailored Dose Reduction Of Tumor Necrosis Factor-Alpha Blocking Agents In Ankylosing Spondylitis Patients With Stable Low Disease Activity
Suzanne Arends^1,2, Eveline van der Veer³, Fleur B.S. Kamps⁴, Monique Efde², Martha K. Leijsma⁴, Hendrika Bootsma¹, Elisabeth Brouwer⁵ and Anneke Spoorenberg^2,4, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ³Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands, ⁴Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁵Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Tumor necrosis factor-alpha (TNF-α) blocking agents are very effective in controlling inflammation and improving clinical assessments in patients with ankylosing spondylitis (AS). In view…
Abstract Number: 1529 • 2013 ACR/ARHP Annual Meeting
Patients With Imaging Abnormalities Of The Sacroiliac Joints Are More Likely To Respond To TNF Alpha Inhibitors In Early Axial Spondyloarthritis. Data From The DESIR Cohort
Anna Moltó¹, Simon Paternotte², Pascal Claudepierre³ and Maxime Dougados⁴, ¹Cochin Hospital, Paris- Descartes University, Paris, France, ²Rheumatology Department, Paris- Descartes University, Cochin hospital, Paris, France, ³Rheumatology, Paris-Est University; LIC EA4393; APHP, Henri Mondor Hospital, Creteil, France, ⁴Université Paris René Descartes and Hôpital Cochin, Paris, France
Background/Purpose: Efficacy of TNF alpha inhibitors (TNFi) has been clearly established in patients with axial SpondyloArthritis (ax-SpA), but its effectiveness and adherence with regard to…
Abstract Number: 1530 • 2013 ACR/ARHP Annual Meeting
Vitamin D Deficiency Is Associated With a More Active and Severe Disease In Early Axial Spondyloarthritis: Data From The DESIR Cohort
Ihsane Hmamouchi¹, Simon Paternotte², Didier Borderie³ and Maxime Dougados⁴, ¹Biostatistics, Epidemiology LBRCE, Mohamed V Souissi University, Rabat, Morocco, ²Rheumatology Department, Paris- Descartes University, Cochin hospital, Paris, France, ³Laboratoire de Biochimie, Hopital Cochin, Paris Descartes University, Pris, France, ⁴Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France
Background/Purpose: Objectives a) to describe the vitamin D status b) to assess the relationship between vitamin D status and disease activity/severity and c) to estimate…
Abstract Number: 1531 • 2013 ACR/ARHP Annual Meeting
Agreement Between Disease Activity States and Improvement Scores As Defined by Bath Ankylosing Spondylitis Disease Activity Index and Ankylosing Spondylitis Disease Activity Score Cut-Off Values
Dilek Solmaz, Pinar Cetin, Ismail Sari, Merih Birlik, Servet Akar, Fatos Onen and Nurullah Akkoc, Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey
Background/Purpose: BASDAI has been extensively used to assess disease activity in ankylosing spondylitis (AS) BASDAI score ≥4 represent high disease activity and has been suggested as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].